SenesTech, Inc.

SenesTech, Inc.

SenesTech, Inc. was founded to address rodent overpopulation through fertility control rather than traditional lethal methods, a model that has drawn interest from family offices and impact investors seeking scalable, humane pest management alternatives. The company went public on the Nasdaq in 2016 under the ticker SNES, raising capital to commercialize its flagship product ContraPest. SenesTech's strategy centers on a single product — ContraPest, a liquid bait that reduces rodent fertility over time. The firm targets municipal, agricultural, and commercial customers, with deployments in cities such as New York and Washington D.C. (per company filings, 2022). The business model relies on recurring revenue from bait contracts rather than single-sale extermination services, though adoption has been slow relative to initial projections. The company reported a net loss of $7.2 million for fiscal year 2023 (per SEC filing, March 2024), reflecting the high costs of sales and marketing relative to revenue, which was $1.8 million for the same period. As of the latest filing, SenesTech employed 22 people (per SEC filing, 2024). It maintains a single headquarters in Phoenix, Arizona (per public records, 2023). The firm's small market capitalization and cash burn rate have led to periodic equity raises, including a $5 million registered direct offering in October 2023 (per SEC filing, October 2023). SenesTech's structural differentiator is its focus on non-lethal rodent control in a market dominated by chemical poisons and traps. The firm holds multiple patents on its fertility-control technology, creating a narrow competitive moat (per USPTO records, 2023). However, the company's inability to achieve profitability and limited commercial traction represent material risks for any investor considering the equity.